Attorneys At Law.

Harmful Drug Exposure

Harmful Drug Exposure Lawyer

For a free, confidential legal consultation, submit your Harmful Drug Exposure injury claim or call 1-800-471-3980 now.

If you are looking for a firm that can handle Harmful Drug Exposure lawsuits, or are simply unsure if you have a case, there is no obligation to discuss your case with one of GPW's attorneys. Contact us today.

About Harmful Drug Exposure


Harmful Drug Exposure news feed.

FDA Issues Public Health Advisory on Vioxx as its Manufacturer Voluntarily Withdraws the Product

September 30th, 2004. (Press Release) The Food and Drug Administration (FDA) today acknowledged the voluntary withdrawal from the market of Vioxx (chemical name rofecoxib), a non-steroidal anti-inflammatory drug (NSAID) manufactured by Merck & Co. FDA today also issued a Public Health Advisory to inform patients of this action and to advise them to consult with ... [More >>]

Merck Announces Voluntary Worldwide Withdrawal of VIOXX®

September 30th, 2004. Merck & Co., Inc. today announced a voluntary worldwide withdrawal of VIOXX® (rofecoxib), its arthritis and acute pain medication. The company's decision, which is effective immediately, is based on new, three-year data from a prospective, randomized, placebo-controlled clinical trial, the APPROVe (Adenomatous Polyp Prevention on VIOXX) trial. The trial, which ... [More >>]

Ephedra Ban (Ephadrine, Ephedrine, Ma Huang)

December 30th, 2003. About Ephedra Ephedra is an adrenaline-like stimulant derived from botanicals that can have potentially dangerous effects on the heart. Ephedra's Adverse Side Effects ... [More >>]

FDA Announces Plans to Prohibit Sales of Dietary Supplements Containing Ephedra; Consumers Advised to Stop Using Ephedra Products Immediately

December 30th, 2003. (Press Release) HHS Secretary Tommy G. Thompson today announced that the Food and Drug Administration (FDA) has issued a consumer alert on the safety of dietary supplements containing ephedra and has notified manufacturers of its intent to publish a final rule on dietary supplements containing ephedrine alkaloids. The rule will state that ... [More >>]

Merck Confirms Favorable Cardiovascular Safety Profile of Vioxx

May 22nd, 2001. In response to news and analyst reports of data the Company first released a year ago, Merck & Co., Inc. today reconfirmed the favorable cardiovascular safety profile of Vioxx(R) (rofecoxib), its medicine that selectively inhibits COX-2. Vioxx was approved by the Food and Drug Administration in May 1999 for the ... [More >>]

Pittsburgh, PA. Greensburg, PA. Johnstown, PA. West Virginia. Saginaw, MI Allen Park, MI.